DOCSLIB.ORG

Original Paper in Vivo Hypolipidemic and Hypoglycemic Effects of Aqueous Extract of Spondias Mombin Leaves and Detoxification Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Original Paper in Vivo Hypolipidemic and Hypoglycemic Effects of Aqueous Extract of Spondias Mombin Leaves and Detoxification Of Available online at http://www.ifgdg.org Int. J. Biol. Chem. Sci. 10(4): 1573-1579, August 2016 ISSN 1997-342X (Online), ISSN 1991-8631 (Print) Original Paper http://ajol.info/index.php/ijbcs http://indexmedicus.afro.who.int In vivo hypolipidemic and hypoglycemic effects of aqueous extract of Spondias mombin leaves and detoxification of reactive oxygen species in alloxan-induced diabetic rats Etah Etah NKANU1*, Sikirullai Olatunde JEJE1, Daniel Ewa IKPI2 and Gabriel Otu UJONG1 1 Department of Human Physiology, Cross River University of Technology, Okuku Campus, Cross River State, Nigeria. 2 Department of Physiology, University of Calabar, Cross River State, Nigeria. *Corresponding author; E-mail: [email protected], Tel: +2347030299991 ABSTRACT The effect of aqueous extract of Spondias mombin leaves extract on lipid peroxidation and antioxidant activity in alloxan induced diabetes was studied. Forty male albino Wistar rats (100-150 g body weight) were used. The rats were randomly selected into four groups containing 10 rats each. Group 1 was the control group and it was placed on normal rat chow. Group 2 was the Spondias mombin (spm) group placed on normal rat chow and given 250 mg/kg extract orally. Group 3 was the alloxan-induced diabetic (150 mg/kg) group (DM) and Group 4 was the diabetic group treated with 250 mg/kg extracts (Dm+spm). At the end of 30 days blood samples were collected by cardiac puncture and used for biochemical analysis. Results obtained revealed that blood glucose level in group 3 (Dm) was significantly higher (p<0.05) than control but the administration of Spondias mombin leaves extract significantly reduced the blood glucose level (p<0.05). Total cholesterol (TC), triglycerides (TG) and Low Density Lipoprotein (LDL) were significantly raised in the diabetic group while High Density Lipoprotein (HDL) was significantly reduced (p<0.05). Treatment with extract decreased TC, TG, LDL but significantly increased the HDL level (p<0.05). Lipid peroxidation was increased in the diabetic group and treatment with extract significantly reduced (p<0.05) the level of lipid peroxidation. Superoxide dismutase (SOD) and catalase (CAT) activities were decreased significantly in the diabetic group. Administration of extracts increased the antioxidant enzymes activities. The result suggests that aqueous extracts of Spondias mombin leaves possess hypoglycemic effects and improve lipid profile of diabetic rats. This effect may be secondary to its ability to reduce oxidative stress. © 2016 International Formulae Group. All rights reserved. Keywords: Diabetes, SOD, CAT, Lipid peroxidation, hypolipidemic, hypoglycemic, Spondias mombin INTRODUCTION the management of various disease conditions. Most plants in every part of Africa are These conditions include cardiovascular used for the treatment of different kinds of diseases, dysentery, heamorrhoids, and ailment and diseases. Spondias mombin is diarrhea (Martinez, 2000). The plant leaves among the notable plants that play vital role in have been reported to contain antiviral © 2016 International Formulae Group. All rights reserved. 2639-IJBCS DOI : http://dx.doi.org/10.4314/ijbcs.v10i4.10 E.E. NKANU et al. / Int. J. Biol. Chem. Sci. 10(4): 1573-1579, 2016 ellagtannins, caffenyl esters and phenolic hypoglycemic and level of oxidative stress acids (Corthout et al., 1994). caused by alloxan-induced diabetes mellitus in In traditional medicine, the extracts of Wistar rats. fresh boiled leaf of Spondias mombin have been reported to be used in the treatment of MATERIALS AND METHODS dizziness, and are said to be strongly Preparation of leaf extract of Spondias abortificient (Offiah and Anyanwu, 1989). mombin Among the Phytochemical components of the The fresh leaves of Spondias mombin leaves of Spondias mombin are alkaloids, were collected, washed and dried in the flavanoids, tannins, saponins and phenolic laboratory for two weeks and the leaves compounds (Nnjoku and Akumefula, 2007). ground to powder. The powdered Spondias Flavanoids as antioxidant, they scavenge free mombin leaves were extracted by the bulk radicals and prevents oxidative cell damage using the soxhlet extraction method. The and also provides anticancer activity. Other liquid extract obtained was slowly evaporated basic function of the flavanoids includes its in vacuo. The total yield was 28.06 g. The ability to protect against allergies, extract was used to prepare the required test inflammation, platelet aggregation and ulcer concentrations. The extract was stored in the (Okolie et al., 2008). According to Iweala et refrigerator at 4 oC. al. (2011), the seed of Spondia mombin possess hypoglycemic effects in alloxan Experimental design induced diabetic rats. However nothing is Forty male albino Wistar rats weighing known about the hypoglycemic effect of the 100-150g were obtained from the Animal leave extract of Spondia mombin in diabetic House of Department of Physiology, Cross rats. Diabetes mellitus is a disease associated River University of Technology, Okuku with defect in glucose metabolism (WHO, Campus, Nigeria. Four groups containing 10 1999) and is linked to oxidative stress induced rats each were randomly selected and used for by hyperglycemia (Iwaela et al., 2000) which the study. All the animals had access to feed manifest into hyperlipidemia and and water ad libitum. Group 1 was the control hypercholesterolaemia (Ross, 1999). It is (cont), fed on normal feed. Group two was the estimated that about 3.2 million people died of Spondias mombin (SPM) group fed on normal diabetes related conditions annually. This feed and administered with 250 mg/kg of situation is worst in developing countries extract. Group 3 was the alloxan induced (150 where the number of people affected is mg/kg) diabetic group untreated (DMU) and expected to increase by 150% by 2030 (Hope, group 4 was the diabetic group treated with 2004). Management of diabetes mellitus the extract (250 mg/kg). Diabetes was induced usually involves adjustment of the patient by intraperitoneal injection of 150 mg/kg lifestyle or in some cases supplementary with bolus of alloxan. Accu check glucometer was agents that lower blood sugar level. Recently used to confirm them diabetic after 3 days. At attentions have been shifted toward the use of the end of 28 days, the animals were fasted for medicinal plant in the management of 12 hours, anesthetized with ether and blood degenerative diseases such as diabetes samples collected via cardiac puncture and put mellitus. Therefore this study is designed to into EDTA blood sample bottles for investigate the effects of aqueous leave extract biochemical analysis. of Spondias mombin on hypolipidemic, 1574 E.E. NKANU et al. / Int. J. Biol. Chem. Sci. 10(4): 1573-1579, 2016 Measurement of biochemical parameters Lipid profile Blood samples were collected by The TC in the diabetic untreated was cardiac puncture, put in EDTA sample bottle. significantly increased (p˂0.05) when Glucose oxidase method of Trinder (1969) compared with the diabetic treated (Table 1). was used for glucose determination. The mean triglyceride (mg/dl) in diabetic To determine total cholesterol level in group was significantly (p˂0.01) elevated blood, Siedel et al. (1983) method was used. compared with the control. Administration of Enzymatic cholesterol colorimetric kit was extract to the diabetic group lowered the TC used for analysis and absorbance measured at level significantly (p˂0.01) by about 19.6%. 550 nm against the reagent blank. Triglyceride The mean level of low density was determined by the method of Sullevian et lipoprotein (LDL-c) in the diabetic group was al. (1985). The equation of Friedwald et al. significantly (p˂0.05) raised but lowered (1972) (LDL =TC-HDL+ TG/2.23) was used remarkably (70.8% and 26.36% respectively) to estimate LDL-c level. following the administration of the extract. Protein was determined according to The high density lipoprotein cholesterol level the method of Lowry et al. (1951) using (HDL-c) significantly (p˂0.05) decreased in standard protein solution. The method of the diabetics when compared to control (Table Buege and Aust (1978) was used to determine 2). lipid peroxidation. The levels of total superoxides dismutase was determined by the Tissue lipid peroxidation and antioxidant method of Misra and Fridovich (1972) while enzyme catalase activity was determine according to At the end of 28 days administration of the method of Sinha (1971). extract, there was significant (p<0.05) increase in lipid peroxidation in the diabetic Data analysis group compared to the control. Lipid All data are presented as the means ± peroxidation was significantly reduced in the Standard Error of Mean (SEM). One way diabetic treated and Spondias mombin group analysis of variance (ANOVA) was used for only (Figure 2). the analysis followed by a post-hoc Turkey’s Superoxide dismutase (SOD) activity HSD test using the SPSS software package was significantly (p<0.05) reduced in the version 13.0. Means was considered to be diabetics compared to the control. There was a significant at p< 0.05. significant increase in SOD activity in both Spondias mombin group and the diabetics RESULTS treated group (47.52%) when compared to the Blood glucose diabetic untreated group (Table 1). As shown in Figure 1, blood glucose Catalase activity was also significantly level was significantly (p<0.05) increased in (p<0.05) lowered in the diabetic group alloxan-induced diabetic rats (115.86 ± 5.0 compared to the control. In the Spondias mg/dl) when compared with control (84.57 ± mombin and diabetics treated groups, catalase 3.0 mg/dl). activity was significantly (p<0.05) increased Following the oral administration of (25%) (Table 1). extract, blood glucose level decreased significantly (p<0.05) to 90.0 ± 2.0 in the DM+SPM group representing about 23% reduction. 1575 E.E. NKANU et al. / Int. J. Biol. Chem. Sci. 10(4): 1573-1579, 2016 Table 1: Effect of aqueous extract of Spondias mombin leaves on lipid profile and antioxidant activity in alloxan induced diabetes mellitus.
Load more

Recommended publications
  • An Educational Booklet for Patients with Familial Hypercholesterolemia
    Illustrations > Jean Lambert Illustrations graphic design > www.mine-de-rien.net graphic Chol/29/P030/01-01/10 NLA An educational booklet for patients with familial hypercholesterolemia This brochure was provided by Genzyme Corporation for use by the Foundation of the National Lipid Association. DR. LEIV OSE www.learnyourlipids.com CONTENTS PART 1 What will you learn from this booklet? 02 FAMILIAL HYPERCHOLESTEROLEMIA PART 1: FAMILIAL HYPERCHOLESTEROLEMIA 03 1 - What is Familial Hypercholesterolemia? 03 WHAT WILL YOU 2 - What is LDL-Cholesterol? 04 3 - What are the causes of FH? 05 LEARN FROM THIS GREAT GRANDMOTHER GREAT GRANDFATHER 4 - When should FH be suspected? 07 FH NON FH BOOKLET? 5 - How is FH diagnosed? 09 6 - How early can FH be diagnosed? 09 Woman You will learn about Familial PART 2: TREATMENT 10 GRANDMOTHER GRANDFATHER Hypercholesterolemia, NON FH FH Woman with FH 1 - How can LDL-Cholesterol be reduced? 10 its cause, and the potential 2 - Step 1: Dietary management of FH 11 Man consequences of this a) How does diet affect LDL-Cholesterol? 11 disease. You will learn b) What sort of diet? 11 Man with FH about high cholesterol 3 - Step 2: Using medication 12 AUNT MOTHER FATHER UNCLE and what this might mean a) How does medication affect LDL-Cholesterol? 12 NON FH FH NON FH FH for your heart and blood b) Which drug treatments reduce LDL-Cholesterol and how? 13 FIGURE 1: 4 - Why is lifelong treatment important? vessels. Most importantly 15 FH is an inherited disease, you will learn how to find PART 3: CARDIOVASCULAR DISEASE AND LIPOPROTEINS 16 which can usually be traced out whether someone in 1 - What is cardiovascular disease? 16 DAUGTER SON over several generations.
    [Show full text]
  • Core Laboratory
    Performance of the vast majority of Hematology, Coagulation, Urinalysis, Clinical Chemistry and Toxicology testing procedures is conducted in the CORE LABORATORY - an advanced, highly automated area where whole blood, serum, plasma, urine and other biological fluid specimens are tested for a comprehensive menu of state-of-the-art laboratory procedures. Significant testing procedures for Clinical Chemistry and Toxicology includes panels currently approved by the Centers for Medicare and Medicaid Services: Basic Metabolic Panel; Comprehensive Metabolic Panel; Liver Function Panel; Renal Function Panel; and Electrolyte Panel. Other key tests include the Lipid Profile (Cholesterol, Triglyceride, HDL- Cholesterol and LDL-Cholesterol), major markers of cardiovascular disease and risk [such as Troponin I, Myoglobin and Beta-type natriuretic peptide (commonly referred to as BNAT or BNP)], critical care analytes, beta-HCG, and significant therapeutic drug levels. Urinary toxicology screens for major drugs of abuse (and/or key metabolites) are also performed. The cornerstones of Hematology testing are analyses of the complete blood count (CBC) and the differential (DIFF). These include evaluation of: (1) white blood cell count and differential with percentage and absolute value given for the leukocyte components; (2) circulating erythrocytes by means of hemoglobin, hematocrit, red blood cell count, and red blood cell indices; and (3) measurement of platelet concentration by count and/or estimation. Morphological variations and changes of cellular constituents are reported. Alteration of any aspect of the hemostatic mechanism may cause abnormal bleeding in a wide variety of familial and acquired disorders. These defects may be differentiated by a profile of significant Coagulation laboratory tests that includes PT, PTT, Fibrinogen, FDP, and D-Dimer for monitoring anticoagulant therapy.
    [Show full text]
  • Genetic Testing for Familial Hypercholesterolemia AHS – M2137
    Corporate Medical Policy Genetic Testing for Familial Hypercholesterolemia AHS – M2137 File Name: genetic_testing_for_familial_hypercholesterolemia Origination: 01/01/2019 Last CAP Review: 07/2021 Next CAP Review: 07/2022 Last Review: 07/2021 Description of Procedure or Service Definitions Familial hypercholesterolemia (FH) is a genetic condition that results in premature atherosclerotic cardiovascular disease due to lifelong exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels (Sturm et al., 2018). FH encompasses multiple clinical phenotypes associated with distinct molecular etiologies. The most common is an autosomal dominant disorder caused by mutations in one of three genes, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), and proprotein convertase subtilisin-like kexin type 9 (PCSK9) (Ahmad et al., 2016; Goldberg et al., 2011). Rare autosomal recessive disease results from mutation in low-density lipoprotein receptor adaptor protein (LDLRAP) (Garcia et al., 2001). Related Policies Cardiovascular Disease Risk Assessment AHS – G2050 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial hypercholesterolemia when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Genetic Testing for Familial Hypercholesterolemia is covered 1. Genetic testing to establish a molecular diagnosis of Familial Hypercholesterolemia is considered medically necessary when BOTH of the following criteria are met: A.
    [Show full text]
  • Inflammatory Mechanisms Affecting the Lipid Profile in Patients with Systemic Lupus Erythematosus CECILIA P
    Inflammatory Mechanisms Affecting the Lipid Profile in Patients with Systemic Lupus Erythematosus CECILIA P. CHUNG, ANNETTE OESER, JOSEPH SOLUS, INGRID AVALOS, TEBEB GEBRETSADIK, AYUMI SHINTANI, MacRAE F. LINTON, SERGIO FAZIO, and C. MICHAEL STEIN ABSTRACT. Objective. Increased low density lipoprotein (LDL) cholesterol and triglycerides, and decreased high density lipoprotein (HDL) cholesterol concentrations are associated with adverse cardiovascular risk in the general population. Patients with systemic lupus erythematosus (SLE) have an altered lipid profile characterized by increased triglycerides and decreased HDL cholesterol concentrations. We examined the relationships between lipid concentrations, cytokines, and inflammatory markers in patients with SLE. Methods. Fasting lipid concentrations, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in 110 patients with SLE. Disease activity was quantified by the SLE Disease Activity Index (SLEDAI), and disease damage by the Systemic Lupus International Collaborating Clinics (SLICC) score. Concentrations of circulating tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and insulin were measured and insulin sensitivity calculated. Results. Lower concentrations of HDL cholesterol were independently associated with higher ESR (p < 0.001), IL-6 (p = 0.02), SLEDAI (p = 0.04), and TNF-α (p = 0.04) after adjustment for age, sex, race, body mass index, insulin sensitivity, and current use of corticosteroids or hydroxychloroquine. Triglyceride concentrations were
    [Show full text]
  • Lipid Profile and Its Relationship with Blood
    Onkar Singh et al. Lipid profile and blood glucose levels in MetS National Journal of Physiology, DOI: 10.5455/njppp.2015.5.051120141 NJPPP Pharmacy & Pharmacology http://www.njppp.com/ RESEARCH ARTICLE Correspondence LIPID PROFILE AND ITS RELATIONSHIP Onkar Singh ([email protected]) WITH BLOOD GLUCOSE LEVELS IN Received 27.08.2014 METABOLIC SYNDROME Accepted 09.09.2014 1 1 2 Onkar Singh , Mrityunjay Gupta , Vijay Khajuria Key Words Metabolic Syndrome; 1 Department of Physiology, Government Medical College, Jammu, India Dyslipidemia; Lipid Pattern; 2 Department of Pharmacology, Government Medical College, Jammu, India Type 2 Diabetes Mellitus Background: Metabolic syndrome (MetS) and its associated factors such as dyslipidemia and hyperglycemia are associated with increased risk of cardiovascular disease (CVD). Aims and Objective: To assess lipid profile and its relation with blood glucose levels in patients with MetS. Materials and Methods: This cross-sectional study included 72 male patients with MetS. Anthropometry, lipid profile, blood glucose, and presence of MetS (JIS criteria) were determined. Results: High triglyceride (TG) level (>200 mg/dL, 44.4%) was the most common dyslipidemia followed by low levels of high-density lipoprotein cholesterol (<40 mg/dL, 19.4%). High total cholesterol levels (>240 mg/dL, 13.8%) and high low- density lipoprotein cholesterol levels (>160 mg/dL, 9.7%) were observed. On comparison, no significant differences in lipid levels of MetS patients with normal fasting glucose, impaired fasting glucose, and type 2 diabetes mellitus were observed. Conclusions: Dyslipidemia was frequent in patients with MetS. High TG was the most common lipid abnormality, and a large number of patients had more than one abnormal lipid parameter.
    [Show full text]
  • Community Lab Costs
    Sickle Cell This tests for the genetic trait which may lead to sickle cell anemia. Osteoporosis Screening This uses ultrasound to screen people for low bone density or osteoporosis and is completed by painlessly scanning the heel. Because osteoporosis rarely causes signs or symptoms until it’s advanced, the National Osteoporosis Foundation recommends a bone density test if you are: • A woman older than age 65 or a man older than age 70 • A postmenopausal woman with at least one risk factor for osteoporosis Community Lab Costs • A man between age 50 and 70 who has at least one osteoporosis (greatly reduced rates) risk factor • Older than age 50 with a history of a broken bone • Taking medications, such as prednisone, aromatase inhibitors or Wellness Panel........................................................................ $20 Fasting anti-seizure drugs, that are associated with osteoporosis Includes screening for glucose, electrolytes, kidney, liver and • A postmenopausal woman who has recently stopped taking thyroid, plus complete blood count and lipid profile hormone therapy • A woman who experienced early menopause Diabetic Screening (A1c)...................................................... $5 The results of this test will indicate if you have or at risk for osteoporosis. Sickle Cell................................................................................ $6 If so, your doctor can offer treatment. PSA (Prostate Screening)...................................................... $8 Breathing Test This measures airflow and lung
    [Show full text]
  • Commonly Used Lipidcentric ICD-10 (ICD-9) Codes
    Commonly Used Lipidcentric ICD-10 (ICD-9) Codes *This is not an all inclusive list of ICD-10 codes R.LaForge 11/2015 E78.0 (272.0) Pure hypercholesterolemia E78.3 (272.3) Hyperchylomicronemia (Group A) (Group D) Familial hypercholesterolemia Grütz syndrome Fredrickson Type IIa Chylomicronemia (fasting) (with hyperlipoproteinemia hyperprebetalipoproteinemia) Hyperbetalipoproteinemia Fredrickson type I or V Hyperlipidemia, Group A hyperlipoproteinemia Low-density-lipoid-type [LDL] Lipemia hyperlipoproteinemia Mixed hyperglyceridemia E78.4 (272.4) Other hyperlipidemia E78.1 (272.1) Pure hyperglyceridemia Type 1 Diabetes Mellitus (DM) with (Group B) hyperlipidemia Elevated fasting triglycerides Type 1 DM w diabetic hyperlipidemia Endogenous hyperglyceridemia Familial hyperalphalipoproteinemia Fredrickson Type IV Hyperalphalipoproteinemia, familial hyperlipoproteinemia Hyperlipidemia due to type 1 DM Hyperlipidemia, Group B Hyperprebetalipoproteinemia Hypertriglyceridemia, essential E78.5 (272.5) Hyperlipidemia, unspecified Very-low-density-lipoid-type [VLDL] Complex dyslipidemia hyperlipoproteinemia Elevated fasting lipid profile Elevated lipid profile fasting Hyperlipidemia E78.2 (272.2) Mixed hyperlipidemia (Group C) Hyperlipidemia (high blood fats) Broad- or floating-betalipoproteinemia Hyperlipidemia due to steroid Combined hyperlipidemia NOS Hyperlipidemia due to type 2 diabetes Elevated cholesterol with elevated mellitus triglycerides NEC Fredrickson Type IIb or III hyperlipoproteinemia with E78.6 (272.6)
    [Show full text]
  • Lipid Profile Abnormalities Seen in T2DM Patients in Primary Healthcare in Turkey: a Cross-Sectional Study Aclan Ozder
    Ozder Lipids in Health and Disease 2014, 13:183 http://www.lipidworld.com/content/13/1/183 RESEARCH Open Access Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study Aclan Ozder Abstract Background: Diabetes is characterized by chronic hyperglycemia and disturbances of carbohydrate, lipid and protein metabolism. We aimed to research association between serum lipid profile and blood glucose, hypothesizing that early detection and treatment of lipid abnormalities can minimize the risk for atherogenic cardiovascular disorder and cerebrovascular accident in patients with type 2 diabetes mellitus. Methods: Fasting blood glucose (FBG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and glycated haemoglobin (HbA1c) levels were evaluated. A hepatic ultrasound was performed for every diabetic to evaluate hepatosteatosis. The study was done from January 2014 to June 2014 among 132 patients with T2DM who were admitted to outpatient clinic of Family Medicine department in a university hospital. The patients whose taking multi-vitamin supplementation or having hepatic, renal or metabolic bone disorders (including parathyroid related problems) were excluded from the study for the reason that those conditions might affect the carbohydrate and lipid metabolism in diabetes. Test of significance was calculated by unpaired student’s t test between cases and controls. Correlation studies (Pearson’s correlation) were performed between the variables of blood glucose and serum lipid profile. Significance was set at p<0.05. Results: Results of serum lipid profile showed that the mean values for TC, TG, HDL and LDL in female patients were 227.6 ± 57.7 mg/dl, 221.6 ± 101.1 mg/dl, 31.5 ± 6.7 mg/dl and 136.5 ± 43.7 mg/dl, respectively.
    [Show full text]
  • Lipid Guidelines 2018: Updates from ACC/AHA Guidelines 2013
    Lipid Guidelines 2018: Updates from ACC/AHA Guidelines 2013 Allen Adolphe M.D., Ph.D. FACP Professor and Vice Chief General Internal Medicine, University of New Mexico Objectives and Disclosures • Disclosures: NIH GRADE Study; Pharmaceutical Trials, none active now • Objectives – Know the four categories of high CVD risk from the ACC/AHA 2013 Lipid Guidelines (ATP IV) – Know what the major philosophical change between ATP III and ATP IV – Know what the ACC Expert Consensus Decision Pathway is and what changes in the ACC/AHA guidelines are suggested ATP IV: a little more abstract ATP III ATP IV • RISK FACTOR COUNTING • THERE IS NO TARGET • TREAT TO LDL GOAL • THE OF • ADDRESS NON-HDL TARGET INTENSITY STATIN THERAPY IS THE FOCUS OF TREATMENT ATP-IV (ACC-AHA 2013 Guidelines) • How many of you have adopted the ATP IV guidelines in your lipid practice by reducing the LDL-C by >50% for those at high risk of CVD? • How many of you believe that if the LDL-C too low it will place patients at risk for adverse effects? • How many of you treat patient with Familial Hyperlipidemia? A Comparative Analysis of Current Lipid Treatment Guidelines RISK ESTIMATORS • Risk estimators are derived from large studies in the United States or Europe. All include age, sex, total cholesterol, HDL-C, and systolic blood pressure as predictors. • However, ethnicity, treatment for hypertension, diabetes, and smoking status are only included in some; thus, patient risk may vary with different estimators. Outcomes are different between risk estimators • Outcome for the FRS is the most inclusive, predicting 10-year risk of coronary heart disease, cerebrovascular events, peripheral artery disease, or heart failure.
    [Show full text]
  • Screening for Lipid Disorder: Systematic Evidence Review
    On December 6, 1999, under Public Law 106-129, the Agency for Health Care Policy Research (AHCPR) was reauthorized and renamed the Agency for Healthcare Research and Quality(AHRQ). The law authorizes AHRQ to continue its research on the cost, quality, and outcomes of health care, and expands its role to improve patient safety and address medical errors. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. Systematic Evidence Review Number 4 Screening for Lipid Disorders Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 http://www.ahrq.gov Contract No. 290-97-0011 Task Order No. 3 Technical Support of the U.S. Preventive Services Task Force Prepared by: Research Triangle Institute University of North Carolina Evidence-based Practice Center Michael P. Pignone, M.D., M.P.H. Christopher J. Phillips, M.D., M.P.H. Carole M. Lannon, M.D., M.P.H. Cynthia D. Mulrow, M.D., M.Sc. Steven M. Teutsch, M.D., M.P.H. Kathleen N. Lohr, Ph.D. B. Lynn Whitener, Dr.P.H., M.S.L.S. AHRQ Publication No. 01-S004 April 2001 The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S.
    [Show full text]
  • Association Between Level of Hba1c and Lipid Profile in T2DM Patients Attending Diabetic OPD at BPKIHS
    Baranwal et.al. Association between level of HbA1c and lipid profile Original Article Health Renaissance 2015;13(3): 16-23 Association between level of HbA1c and lipid profile in T2DM patients attending diabetic OPD at BPKIHS JK Baranwal 1, R Maskey 2, S Majhi 3, M Lamsal 1, N Baral 1 Department of Biochemistry 1, Department of Internal Medicine 2, Department of Biochemistry B.P. Koirala Institute of Health Sciences, Xavier University 3 Abstract Hyperglycemia, dyslipidemia and coronary artery disease relate well with each other in type 2 diabetes and it has been proposed that higher prevalence of cardiovascular disease in type 2 diabetes is due to chronic uncontrolled hyperglycemia. Our study aimed to find utility of Hba1c as indicator of dyslipidemia in patients with type 2 diabetes mellitus. We enrolled 168 T2DM patients in our study and collected venous blood samples in both plain and EDTA vials after a fast of minimum 8 hours. Biochemical analysis was done in fully automated analyzer cobas c311. HbA1c was found to have significant positive correlation with total cholesterol, LDL-C, and triglyceride and significant negative correlation with HDL-C and HDL/LDL ratio. The mean value of TC, LDL-C and TG was found to be lower in patients with good glycemic control than those with poor glycemic control. But, mean value of HDL and HDL/LDL ratios were found to be higher in patients with good glycemic control than those with poor glycemic control. These differences were significant at the level of p <0.05. Our study suggests additional use of HbA1c as indicator of dyslipidemia.
    [Show full text]
  • Cholesterol and Kidney Disease What You Need to Know
    CHOLESTEROL AND KIDNEY DISEASE WHAT YOU NEED TO KNOW WHAT IS CHOLESTEROL? Ã Cholesterol is a type of fat (lipid) found in your blood and other parts of the body. Your body needs small amounts of cholesterol to work normally. Your body can make cholesterol, or get it from certain foods. Ã There are different kinds of cholesterol: Ã LDL cholesterol: Known as the “bad” cholesterol. Too much of it can cause harmful buildup and blockage in your arteries (a type a blood vessel) and causes heart and blood vessel disease. Ã HDL cholesterol: Known as “good” cholesterol. It helps prevent cholesterol from building up in your arteries. Ã Triglyceride: Another type of fat or lipid. Too much of it can also increase your risk for heart and blood vessel disease. Ã A blood test called a complete lipid profile is used to test cholesterol levels. A lipid profile measures for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. WHAT IS CKD? Ã Chronic kidney disease (CKD) is a loss of kidney function that happens gradually, and which has been present for 3 or more months. In CKD, the kidneys become less able to perform many vital functions, including removing wastes from the body, balancing the body’s fluids, regulating blood pressure, producing red blood cells, and maintaining healthy bones. Ã Urine and blood tests can check for signs of CKD. Albumin-to-creatinine ratio (ACR) is a urine test that checks for high protein in the urine, which is a sign of kidney damage. Glomerular filtration rate (GFR) is a blood test that checks how well the kidneys are filtering.
    [Show full text]